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Background: Oral tongue squamous cell carcinomas (TSCC) are a unique subset of head and neck cancers with a
distinct demographic profile, where up to half of the cases are never smokers. A small proportion of patients with
OSCC are known to respond to EGFR TKI. We used a high-sensitivity mass spectrometry-based mutation profiling
platform to determine the EGFR mutation status, as well as other actionable alterations in a series of Asian TSCC.
Methods: 66 TSCC patients treated between 1998-2009 with complete clinico-pathologic data were included in this
study. Somatic mutation profiling was performed using Sequenom LungCarta v1.0, and correlated with clinical
parameters.
Results: Mutations were identified in 20/66(30.3%) of samples and involved TP53, STK11, MET, PIK3CA, BRAF and
NRF2. No activating EGFR mutations or KRAS mutations were discovered in our series, where just over a third were
never smokers. The most common mutations were in p53 (10.6%; n = 7) and MET (10.6%, n = 11) followed by STK11
(9.1%, n = 6) and PIK3CA (4.5%, n = 3). BRAF and NRF2 mutations, which are novel in TSCC, were demonstrated in
one sample each. There was no significant correlation between overall mutation status and smoking history (p = 0.967)
or age (p = 0.360). Positive MET alteration was associated with poorer loco-regional recurrence free survival (LRFS) of
11 months [vs 90 months in MET-negative group (p = 0.008)]. None of the other mutations were significantly correlated
with LRFS or overall survival. Four of these tumors were propagated as immortalized cell lines and demonstrated the
same mutations as the original tumor.
Conclusions: Using the Sequenom multiplexed LungCarta panel, we identified mutations in 6 genes, TP53, STK11,
MET, PIK3CA, BRAF and NRF2, with the notable absence of EGFR and HER2 mutations in our series of Asian OSCC.
Primary cell line models recapitulated the mutation profiles of the original primary tumours and provide an invaluable
resource for experimental cancer therapeutics.
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Oral squamous cell carcinoma (OSCC) is a significant
world-wide public health threat accounting for approxi-
mately 270,000 cases with 145,000 deaths annually [1,2].
The highest prevalence is seen in developing countries
and five-year survival rates remain less than 50% [1-3].
The majority originate from the anterior tongue, and less
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unless otherwise stated.mouth, retromolar trigone and hard palate. Several reports
have suggested an increase in incidence of OSCC over re-
cent years, afflicting not only those of lower socioeco-
nomic status and developing countries, but also in
developed countries such as the US and UK [4-7]. More-
over, a proportion of cases occur in younger patients who
are never smokers, with no relation to betel nut chewing
or smoking, common risk factors for oral cancers [8,9].
There is also evidence to suggest that the various subsites
within the oral cavity exhibit significant differences in clin-
ical behavior that are not attributable to the pathogenesis
alone [10,11]. This has prompted several investigators to
focus studies on specific subsites, including large scale. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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national Cancer Genome Consortium (ICGC) [12].
The rapidly expanding repertoire of targeted therapeu-
tics against key somatic alterations has led to increased
endeavors towards pathway-driven approaches to treat-
ing cancer. For example, head and neck and lung can-
cers are well known to have activated EGFR pathway,
and this has led to focused development of drugs that ei-
ther directly inhibit the EGFR receptor such as mono-
clonal antibodies like cetuximab, block the tyrosine
kinase activity (small molecules including gefitinib, erloti-
nib, afatanib etc) or molecules that block the downstream
signal transduction cascade (targeting Phosphoinositide 3-
kinase (PI3K), mammalian target of rapamycin (mTOR)
etc) [13]. Specific activating EGFR mutations act as a pre-
dictive marker for tyrosine kinase inhibitors such as gefi-
tinib and erlotinib in NSCLC, and have conferred
significant improvement in overall survival [14]. Clinical
activity of EGFR tyrosine kinase inhibitors (TKI) has also
been examined in head and neck cancer, where responses
have been seen in up to 15% but there is no correlation
between response and EGFR mutations [15-24]. Few stud-
ies have looked for EGFR mutations and other “actionable
mutations” in OSCC, and most to date have been con-
ducted in small heterogeneous HNSCC patient cohorts.
Studies focused on oral or tongue squamous cell carcin-
oma show possible population differences in prevalence
for EGFR mutation rates, suggesting ethnic differences
may exist [24-37]. Similarly, large scale sequencing efforts
in HNSCC by several collaborative groups have focused
mainly in Caucasian populations, revealing common mu-
tations in genes such as p53, p16, Notch, FAT1, H-Ras
and Caspase8 [24,26,27,38]. Recently Zanaruddin et al. re-
ported the use of Sequenom Oncocarta to profile 112 oral
SCC samples in Asian patients [39]. While potentially ac-
tionable mutations such as PIK3CA and HRAS were re-
ported in that study, tongue cancers only comprised 30%
of patients.
Due to the potential similarities among aerodigestive
tract cancers, we adopted the Sequenom LungCarta
panel to comprehensively evaluate a set of 66 Asian
tongue cancers for EGFR mutation status, as well as
other commonly implicated “actionable” or “druggable”
oncogenes and tumour suppressor genes and correlated
these with clinic-pathologic and outcome data.
Methods
Patients and tissue collection
Patients were identified from an institutional database of
consecutive patients treated at the National Cancer Centre
Singapore (NCCS) between January 1998 and March
2009. Included patients were confirmed to have a histo-
logical diagnosis of squamous cell carcinoma involving the
anterior tongue, with complete clinico-pathologic dataand fresh, frozen tumor samples available. Treatment de-
cisions were made in weekly multi-disciplinary meetings
and recorded prospectively. Only patients with no prior
treatment for their cancers were included in this study
and all patients were treated with upfront surgery followed
by adjuvant therapy if applicable. Fresh tumor samples for
sixty-six patients were retrieved from Singhealth Tissue
Repository, with standardized written consent for use of
clinical material (with covers tumor tissue, blood or other
clinical specimens) and clinic-pathologic data for research.
Both this study and the tissue collection/consent protocol
have been approved by the Singhealth Centralized Institu-
tional Review Board.
Tissue preparation and DNA extraction
For all samples, tumor content was first determined by
microscopic examination of hemotoxylin and Eosin (H&E)
stained sections of the tissue by a board-certified path-
ology (TKL). DNA was only extracted from specimens de-
termined to have > 50% tumor content. DNA extraction
was performed using a 3 mm × 3 mm section of fresh-
frozen tissue using the Qiamp DNA extraction kit
(Qiagen, Valencia, CA) according to the manufacturer’s in-
structions. However, the sample DNA was eluted in mo-
lecular grade water instead of TE Buffer. The DNA
concentration and purity were quantified and assessed
using the Nanodrop 2000 spectrophotometer (Thermo
Scientific, Wilmington, DE). All samples yielded excellent
DNA quality with A260/A280 ratio greater than 1.60.
Somatic mutation profiling using Sequenom LungCarta v1.0
Somatic mutation profiling was accomplished by using the
Sequenom LungCarta v1.0 panel (http://www.sequenom.
com) (Sequenom, San Diego, CA). The panel interrogated
214 somatic mutations across 26 oncogenes and tumor
suppressors using the MassARRAY 4 System using multi-
plex PCR (Sequenom, San Diego, CA). Targeted mutation
profiling was performed using the Sequenom Massarray 4
platform (Sequenom, San Diego, CA). Samples were
evaluated for 214 mutations in a 24-multiplex PCR for-
mat using the LungCarta panel and analyzed on the
matrix-assisted laser desorption ionization-time of flight
mass spectrometry (MALDI-TOF) Sequenom platform.
LungCarta panel provides evaluation of 214 somatic mu-
tations in 26 oncogenes and tumour suppressor genes
acting in key pathways in lung cancer (Table 1). Data ex-
traction was performed using Sequenom MassArray
Typer Analyzer software. Mutations were determined
using a minimum 10% threshold of the mutant allele
peak.
An ion exchange resin (CLEAN Resin, Sequenom, San
Diego, CA) was used to remove salt adducts. 41 μl of
water was added to give a final volume of 50 ul after
which the resin was added into the wells. The plates
Table 1 LungCarta 1.0- lung panel gene targets
Gene Mutation Gene Mutation
AKT1 E17K MET N375S, 982_1028del47
ALK C1156Y, L1196M NOTCH1 H2276fs*79, D1643H, R2328W, T1997M, V1672I,
V2444fs*35
BRAF D594G/M, G469S/E/A/V, L597Q/V, V600E/K/M NRAS Q61E/K/H/L/R/P
DDR2 C580Y, D125Y, G253C, G505S, G774E/V, I120M, I638F, L239R, L63V, T765P NRF2 D29H, D77N/A, E79Q/K/G, G31A, G81D, R34Q,
EGFR R108K, T263P, A289V, G598V, E709K/H, E709A/G/V, G719S/C/A/D,
G719S/C/A/D, M766_A767insAI, D761Y/N, S768I, R776C/M, V769_D770insASV,
V769_D770insCV, D770_N771 > AGG/V769_D770insASV/V769_D770insASV,
D770_N771insG, N771_P772 > SVDNR, P772_H773insV, H773 > NPY,
H773_V774insNPH/PH/H, V774_C775insHV, T790M, L858R/M, L861Q,
E746_T751del, E746_A750del, E746_T751del, E746_T751del, S752D,
L747_E749del, L747_T750del, L747_S752del, L747_T751del, L747_S752del,
P753S, A750P, T751A, T751P, T751I, S752I/F, S752_I759del, L747_Q ins,
E746_T751del, I ins (combined), E746_A750del, T751A (combined),
L747_E749del, A750P (combined), L747_T750del, P ins (combined),
L747_S752del, Q ins (combined), T854A
NTRK1 Q80*, R119H, S326R
EPHA3 A435S, D446Y, S449F, D806N, G187R, G518L, K761N, G766E, M269I,
N379K, N85S, S229Y, T166N, T37K, T393K, W250R
NTRK2 Q666R, C45F, G261R, L138F, L670M, L755L
EPHA5 D493Y, G582E, M1034I, N1032S, R1007Q, S566Y, S810I, T856I NTRK3 I769N, L152I, L248M, L270M, L336Q, S184C,
T283K, V307L, R271F
ERBB2 M774_A775insAYVM, A775_G776insAYVM PIK3CA E542Q/K, E545Q/K. H1047Y/R/L
FGFR4 P672T, H192fs*19 PTCH1 R1308G, R682L, S1326fs*46
JAK2 L609S, P503L, R1122P, Y931C PTEN R233*
KRAS G12S/V/F/R/A/C/D, G13C/S/A/V/DQ61L/R/P/H/E/K PTPN11 E76V
MAP2K1 D67N, K57N, Q56P PTPRD D1162N, D154Y, I44I, L1036Q, P1809R, R1536L,
R584S, S1703R, T337A, V483E
STK11 A347fs*13, A43_L50del6, D327fs*10, E120*, E165*, E223*, E70*, E70fs*26,
F354L, G163C, G188fs*99, G196V, G56fs*4, G56W, G91L, H174R, I26fs*25,
K191*, K78E, L285Q, L50_D53del4, M51fs*14, P179L, Q123R, Q137*, Q159*,
Q170*, Q220*, Q37L, R426W, R86G, V197fs*69, V236fs*30, Y272Y
TP53 G245C/S, G245D/V, R158C/G/L/P, R175L/H,
R248L/Q/R/W, R249S/W/M, R273C/H/L/P,
R282G/W, V157F, Y163C,R175L/H Y220C
*Frameshift or truncating mutation.
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samples were transferred onto the SpectroChip-II (96-
well to 96-chip configuration) using the MassARRAY
Nanodispener RS1000 (Sequenom, San Diego, CA). The
dispense speed was at 70 mm/sec but was adjusted ac-
cordingly to ensure a consistent spotting volume range
of 8 to 10 nL with a standard deviation of less than 3.5.
The samples were resolved using the Matrix-Assisted Laser
Desorption/Ionization Time-of-Flight (MALDI-TOF) mass
spectrometer (Sequenom, San Diego, CA).
Data analysis
Mutational analysis was accomplished using the Sequenom
Typer Analyzer 4.0 software (Sequenom, San Diego, CA).
The mutation detection threshold was set at 10%. The sys-
tem provided a mutation list that showed the mutations
that were picked up by the mass spectrometer. The muta-
tions were sorted according to 3 different confidence
levels (High, Medium and Low) based on peak height,
morphology, statistical Z-score and allele frequencies
[40,41]. For all medium and high confidence calls, the
electrophorograms were manually checked. For difficultcases, a second opinion was required. Only cases regarded
as true are included in this list, and all the true cases in
this situation were called with high confidence (see
below). These experiments and analysis were performed
in parallel with a series of lung cancer primary tissue and
cell lines which served as positive controls for a range of
mutations [40].
Statistical analysis
Statistical analyses were performed using SPSS software.
Student’s t test was used to compare group means while
chi-square test and Fisher’s exact test were used to
analyze other factors. Mean overall survival (OS) and
disease-free survival (LRFS) were calculated. Kaplan-
Meier plots were plotted and log-rank test was per-
formed to compare the plots. In all statistical analyses, a
p value of less than 0.05 was considered statistically
significant.
Results
Details of patient characteristics are shown in Table 2. In
this cohort, 46 (69.7%) were male and 37 (56.1%) were
Table 2 Clinico-pathologic characteristics of patients with
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(range: 22-89 years). The majority of patients had locally
advanced disease (T3/T4) (n = 40/60.6%). All patients in
this cohort underwent surgery as the primary modality
of treatment, and 36 (54.5%) received adjuvant radiation
or chemo-radiation therapy. Patients were followed up
for a median of 18 months (Range: 3 - 60 months). Dur-
ing this time period, there were 28 (42.4%) recurrences
and 15 (22.7%) deaths. These were all cancers of the an-
terior tongue, and there was no evidence of involvementof human papillomavirus (HPV) in any of the tumors
(manuscript in preparation- Iyer NG, Tan DSW).
Analyses of the Sequenom data showed that in total
there were 42 high, 60 medium and 353 low confidence
calls. Manual verification confirmed that of these 24 al-
terations were deemed to be true an included in further
analysis, and all of these were derived from high confi-
dence calls. The 24 alterations were identified in 20
(30.3%) tumors using the LungCarta 1.0 panel (Table 2).
These were distributed across six genes: TP53, STK11,
MET, PIK3CA, BRAF and NRF2 and the distribution of
mutations across samples are indicated in Figure 1.
There were thirteen unique alterations identified, with
16 tumors having a single variations and four tumors
having two separate variations (Table 3). The commonest
alterations seen were MET (10.6%; n = 7), TP53 (10.6%;
n = 7), STK11 (9.1%; n = 6). Three PIK3CA mutations
were “activating” (one with E542K and two with H1047N
mutations). One tumor harbored a BRAF (D594G) muta-
tion and another with a mutation in NRF2 (G31A), both
of which are novel in TSCC, and the mutations have been
validated through next-generation target re-sequencing of
the same samples (manuscript in preparation). Tumor
cells were propagated in culture as previously described
[42]. In samples identified to have mutations, four (out of
six attempted) have been successfully propagated in cul-
ture as cell lines: NPC7, TM24, TM44 and TM47 and pro-
filing the cell lines confirmed that these harbored the
same genetic alterations as the primary tumor they were
derived from (Table 3).
There was no significant association between smoking
history and the presence of any mutation detected by
the LungCarta panel (p = 0.967), or specific alterations in
MET (p = 0.806), p53 (p = 0.520) and STK11 (p = 0.105)
(Table 3). There was also no correlation between patient
age and mutation status (p = 0.360). With regards to out-
come analyses, there were no significant correlations be-
tween the presence of any mutation and overall survival
(OS) or loco-regional recurrence-free survival (LRFS).
Median OS was 78 and 106 months (p = 0.711), while
median LRFS was 56 and 93 months (p = 0.670) for pa-
tients with and without any mutations detected by this
assay respectively. Similarly, there was no correlation be-
tween the presence of p53 or STK11 mutations and out-
come. Interestingly, however, the presence of the MET
N375S variant was associated with poorer loco-regional
recurrence rates compared to patients who did not har-
bor this mutation: median LRFS of 11 versus 90 months
respectively (p = 0.008) (Figure 2a). A trend to poorer
survival was also seen when analyzing overall survival,
where the median OS was 31 months in patients with
MET mutation compared to 103 months in patients
without although this was not statistically significant
(p = 0.287) (Figure 2b).
Figure 1 Co-mutation map of samples identified to have at least one mutation in MET, TP53, STK11, PIK3CA, NRF2 and BRAF.
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Oral squamous cell carcinoma remains a devastating dis-
ease with few treatment options in the metastatic set-
ting. In this study, we used a panel designed for lung
cancer to identify mutations in oral tongue cancer. OfTable 3 Specific mutations and clinic-pathologic features sam
Sample Gene Mutation TNM Overall
stage
Age
Tumors with a sin
2000294 MET N375S TxN2bM1 4 53
20021078 STK11 F354L T4aN1M0 4 79
21789206 PIK3CA E542K T4aN0M0 4 54
22873606 TP53 R175H T4aN0M0 4 75
27197906 PIK3CA H1047R T4aN0M0 4 56
NPC7* MET N375S T4N2bM0 4 22
TM24* TP53 R282W T2N2bM0 4 60
TM47* MET N375S T4aN2cM0 4 76
93488640 NRF2 G31A T2N1M0 3 61
51236487 TP53 R273P T2N0M0 2 60
84033237 TP53 R273C T4aN2bM0 4 56
980003 STK11 F354L T2N0M0 2 39
YT3** MET N375S T3N0M0 3 52
YT4 BRAF D594G T1N0M0 1 42
990386 TP53 R175H T4aN0M0 4 63
2000665 MET N375S T4aN2bM0 4 53
Tumors with two se
980398 MET N375S T2N1M0 3 61
TP53 G245S
1784450 MET N375S T4aN2cM0 4 66
STK11 F354L
20020797 STK11 F354L T4aN2cM0 4 69
TP53 Y163C
TM44*** PIK3CA H1047L T2N2bM0 4 62
STK11 F354L
*Successfully propagated as cell line.
**Refused conventional treatment and lost to follow-up.
***Successfully propagated as cell line, patient had a 30-day mortality after primarythe mutations tested, we only identified alterations in six
genes in only 20 samples - TP53, STK11, MET, PIK3CA,
BRAF and NRF2. Importantly, EGFR and KRAS mutations
were not found in Asian tongue cancers, and this repre-









/M Ever Yes Recurrence 7
/M Ever Yes No Recurrence N.A.
/M Ever Yes Recurrence 33
/M Ever No Unknown N.A.
/M Ever Yes Unknown N.A.
/F Ever Yes Recurrence 6
/M Ever Yes Recurrence 15
/M Ever Yes Recurrence 6
/M Never Yes Recurrence 31
/M Never Yes Unknown N.A.
/M Never No Recurrence 24
/M Never No Unknown N.A.
/F Never No Unknown N.A.
/F Never No No Recurrence N.A.
/M Unknown Unknown No Recurrence N.A.
/F Unknown Yes No Recurrence N.A.
parate mutations
/M Never No No Recurrence N.A.
/M Ever No Recurrence 5
/M Ever Yes No Recurrence N.A.
/M Ever Yes No Recurrence N.A.
surgery.
Figure 2 Kaplan-Meier plots showing (a) Locoregional recurrence-free and (b) overall survival in patients with and without the MET
N375S variant in the entire cohort. P-value is computed based on the log rank test. Locoregional recurrence rates are significantly higher in
patients with the MET 375S variant compared to those without.
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horts, such as a large series from Korea, identified up to
14% of EGFR mutations in oral tongue SCC (n = 70), sug-
gesting that population differences likely exist [36]. Inaddition, we did not observe any relationship between age,
tobacco use and the prevalence of the mutations tested.
p53 mutations were the most common abnormality
identified in 10.6% (7/66) of our patient cohort. While
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LungCarta only screens for twelve commonest hotspot
mutations in the DNA binding domain, it may also re-
flect the high proportion of never smokers in our cohort.
A recent study in Asian head and neck squamous cell car-
cinoma found that p53 mutations occurred in approxi-
mately 30% of HNSCC, in contrast to 60-80% in patients
with risk factors such as smoking [43]. We did not find
any significant relationship between p53 mutations and
outcome, although this is limited by the small sample size.
The other common alteration identified in this panel
is a specific MET variant (MET N357S), identified in
10.6% (7/66) of this cohort [44,45]. The therapeutic role
for inhibiting the MET pathway has yet to be validated,
and several trials evaluating targeting MET are ongoing
[46-48]. While this is likely a germline variant more
commonly present in Asians (13%), it appears to confer
resistance to MET inhibition by inhibiting ligand binding,
suggesting that these patients would not benefit from cur-
rently available MET inhibitors [49]. Consistent with its
role in cancer development, we found that patients with
the variant had a poorer outcome than their wild type
counterparts, with median loco-regional recurrence-free
survival of 11 months compared to 90 months in patients
without wild type MET (p = 0.008). Notwithstanding,
these results warrant further investigation and should be
validated in a larger series, to determine the prognostic
value of MET alterations in HNSCC.
Other significant actionable alterations include activat-
ing mutations in PIK3CA (seen in 3 patients in our co-
hort) and STK11 (seen in six patients). These mutations
have been described in HNSCC at similar frequencies
[26,38,50] and are important considerations when plan-
ning future targeted therapy trials in TSCC. Two further
mutations identified in this study are novel for TSCC.
First, the BRAF mutation (D594G) seen here in one pa-
tient has not been previously reported in TSCC, and in-
deed other BRAF mutations are also exceedingly rare in
HNSCC (<2%) [51]. The role of BRAF inhibitors target-
ing non-BRAF V600E cancers remains to be elucidated,
although promising activity has been reported [52,53].
NRF2 mutation was also identified in this cohort consist-
ent with the The Cancer Genome Atlas (TCGA) database
where mutations in NFEL2 (which is the gene for NRF2)
occur in 6% of HNSCC [24]. NRF2 is a transcription factor
that regulates cellular response to oxidative stress by indu-
cing the expression of cytoprotective proteins. It is often
overexpressed in human cancers and somatic mutations
have been detected in lung cancer [54-56].
The paucity of mutations found using the LungCarta
panel suggests that profiling of head and neck cancers
would require a more customised approach and a better
design of a panel focused on head and neck cancers, and
this is in our future pipeline. It is however imperative toensure high-tumor percentage in tissues examine to en-
sure that a lack of mutations reflects a true negative re-
sult rather than false negatives due to a high proportion
of normal cells. If necessary this can be mitigated by
macro- or micro-dissection to enrich for tumor cells.
Large scale next-generation sequencing efforts from or-
ganizations such as TCGA and ICGC would be invalu-
able in delineating the molecular basis of OSCC. The
challenge for the post-genomic/post-discovery era re-
quires implementing pragmatic strategies to identify al-
terations and pathways that are therapeutically tractable.
In this regard, mass spectrometry based mutation profil-
ing is a robust technique that can be applied on frozen
or formalin-fixed embedded tissue, and is particularly
well-suited for multiplexed screening of hotspot alter-
ations in large patient cohorts [40].
Other issues in this study include a lack of normal pa-
tient DNA to confirm that these finding are truly som-
atic. However, with increasing data available form large
scale sequencing efforts and data available in the Cosmic
database, panels can be specifically designed to only
examine alterations know to be somatic. Notwithstand-
ing it is also important to consider germline variants
that can have effects on outcome and therapeutic deci-
sions. The other deficiency with this approach is that it
is focused on hotspot mutations which are predictable
and limited, and hence not effective in detecting inactivat-
ing mutations which tend to be more widely distributed.
In this regard, a capture technique (such as those offered
by Ion Torrent or Sureselect systems) may be more inclu-
sive. However, unlike Sequenom, the latter often require
validation using Sanger sequencing to confirm findings.
This study relied on the availability of sufficient tumor
specimen to perform these analyses; hence there were
fewer small, early T-stage tumors in our cohort than nor-
mally seen in the clinic, despite being a consecutive series.
In conclusion, we confirm that common activating
EGFR mutations and KRAS mutations are not present
in a large cohort of Asian tongue cancers. Molecular
profiling using Sequenom MA4 is a robust, reproducible
technique in determining clinically relevant mutations e.g.
PIK3CA [39,40]. Patient derived cell lines that recapitulate
specific genetic changes in the original tumour are import-
ant discovery tools that will facilitate further understand-
ing of cell context-specific factors of genetic alterations.
Future design of a specific HNSCC panel should take into
consideration important actionable mutations identified
through the ongoing large scale sequencing efforts.Abbreviations
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